Pharmaceutical Giant Expands Stake in Subsidiary with Strategic Acquisition Pharmaceutical Giant Expands Stake in Subsidiary with Strategic Acquisition The company's board approved the purchase of 8,454 equity shares, representing a 3.73 per cent stake in Havix. Kiran Shroff / Wednesday, March 12, 2025 / Article rating: 3.3 The acquisition is expected to be completed within ten days, pending requisite approvals under the Foreign Exchange Management Act, 1999.